top of page
Our technology
Revealing the full picture of disease
Our platform detects disease-specific glycoforms - the unique sugar structures on proteins that change as conditions develop. By measuring these glycoforms directly, our tests deliver higher accuracy, reduce diagnostic uncertainty, and provide earlier answers for women’s health.
The Science
-
Glycoprotein – A protein with sugar(s) attached
-
Glycan – The sugar molecule itself
-
Glycoform – A specific variant of a glycoprotein defined by its sugar pattern
Altered glycoforms have been linked to cancers, inflammatory disorders, and autoimmune diseases. Our platform is designed to find and measure these changes.
Features and benefits
Our proprietary Lectin Magnetic Bead Array–Mass Spectrometry platform offers:
Innovative Technology:
The proprietary LeMBA-MS platform powers ProSeek’s glycoform biomarker discovery and multi-biomarker tests, enabling superior diagnostic accuracy and reliability.
Regulatory Readiness:
ProSeek’s tests are developed to meet and exceed stringent regulatory standards, fostering trust and confidence among healthcare providers, patients, and reimbursement entities.
Seamless Integration:
Compatible with standard clinical mass spectrometry setups, ProSeek’s tests minimize barriers to adoption for pathology laboratories, ensuring effortless implementation.
Scalability:
ProSeek’s modular and adaptable product design supports future expansions into additional diagnostic applications, addressing unmet needs in women’s health.
Clinical Impact:
By supporting accurate triage and precise differentiation between benign and malignant conditions, ProSeek’s tests reduce diagnostic delays, improve treatment pathways, and enhance overall patient care.
Proven impact
Proof of concept completed: esophageal adenocarcinoma biomarkers licensed to Proteomics International in June 2022
feature publications
Feature Publications
bottom of page